CD19 and systemic lupus erythematosus: In another study by Mackensen et al., five patients with SLEDAI-2K (with Systemic Lupus Erythematosus Disease Activity Index-2000) scores of 8–16 who had previously failed multiple therapies were enrolled; these patients presented significant decreases in the SLEDAI-2K score, proteinuria, and anti-dsDNA levels and increases in complement levels at 3 months after anti-CD19 CAR T-cell therapy.